FDA panel: Don't compound Vioxx, Bextra, oxy-ER
This article was originally published in Scrip
A decade after Merck yanked Vioxx and Pfizer withdrew Bextra from the market because of cardiovascular concerns associated with the anti-inflammatory drugs, an FDA panel of outside experts on 23 February said those drugs' active ingredients – rofecoxib and valdecoxib, respectively – should not be compounded by US pharmacists.
You may also be interested in...
FDA’s Pharmacy Compounding Advisory Committee votes to place coated modified release drugs on the “difficult-to-compound” list, thus barring these drugs from being compounded in the foreseeable future. The committee agreed with FDA’s recommendations that the complex formulation and the difficulty in manufacturing them precludes them from being compounded at the current time.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.